NBS >>> Investment Highlights

Divested ownership interest in Suzhou Erye Pharmaceutical Co, increasing its cash position by $12,280,000 - Already received $1,228,000 (10%)

Acute Myocardial Infarction (AMI) therapeutic product development team enrolled the first patient in the PreSERVE Phase 2 clinical trial

Our Progenitor Cell Therapy (PCT) CDMO service business continues to grow and has added new clients in later stage clinical trials setting the stage for expansion into larger and substantially more lucrative commercial manufacturing contracts

Jonathan Sackner-Bernstein, MD, FACC joined the Company. He was Associate Center Director for Technology and Innovation at the U.S. Food and Drug Administration's Center for Devices and Radiological Health

Actively pursuing additional strategic relationships with major pharmaceutical and biotechnology companies in 2012

WBB Securities LLC - UPGRADED TO STRONG BUY - $2.00 12 MONTH TARGET

Symbol is NBS
News Link: http://finance.yahoo.com/q?s=nbs&ql=1



NeoStem Fact Sheet Quick Recap - see below or Full FactSheet PDF link here

June 22, 2012

Fast Facts

Name: NeoStem, Inc.

Industry: Biotech / Cell Therapy

Ticker (Exchange): NBS (NYSE MKT)

All figures as of 6/18/12 except where noted

Stock Price: $0.47

52 Week Range: $0.30 – 1.76

Market Cap: $62.99 million

Average Volume (3 mos): 1,079,033

Shares Outstanding: 129.9 million*

*As of March 31, 2012

NeoStem Subsidiaries



Established Leader in Cell Therapy Services

150 years of combined management expertise in manufacturing, regulatory and commercialization for therapeutics development

$8-10 million in annual historic revenues

Manufactured 30,000+ cell therapy product procedures and delivered 6,000+ cell therapies to patients worldwide for more than 100 clients

50,000 square feet of cGMP manufacturing capability located in North America (East Coast and West Coast)

Large scale manufacturing for clients allows lower costs for internal cell therapy development



•         Establish early partnering relationships with goals of commercial manufacturing, equity participation and back-end royalties





Emerging Leader in Cardiovascular Cell Therapy

Lead product, AMR-001, an autologous adult stem cell therapy for the prevention of major adverse cardiac events following acute myocardial infarction (AMI)

Launched Phase 2 clinical trial in 1Q-2012, data readouts expected 2H-2013

Potential for multiple indications beyond STEMI (i.e., congestive heart failure, other related vascular insufficiencies)


PreSERVE AMI Trial Phase 2 Clinical Plan

Indication    Post-AMI preservation of cardiac function
Number of Subjects, Sites    160 patients, 34+ sites
Primary Endpoint    Increased cardiac perfusion
Amorcyte: Using The CD34+ Natural Repair Mechanism

The body attempts to rescue damaged tissue to prevent ventricular remodeling:

A distress signal (HIF) is induced by hypoxia in the peri- infarct zone

HIF induces syntheses of SDF and VEGF, which mobilize CD34+CXCR4+ cells

The mobilized cells are trophic to the peri-infract zone, preventing apoptosis and effecting neoangiogenesis

AMR-001 is a homogeneous and highly purified cell population enriched for CD34+CXCR4+ cells




In Partnership with Becton Dickinson (20% Owner)

Immunotherapy Platform

• Immune mediated diseases are a result of imbalance between T effector cells and T regulatory cells

• T-reg therapy represents a novel approach for restoring immune balance by enhancing T-reg cell number/function



Opportunities in Regenerative Medicine

Cellular Differentiation with an Eye Toward Macular Degeneration



• Very small embryonic-like stem cells, shown to have several characteristics generally found in embryonic stem cells

• Activities have received awards of > $2.5 million to support this work

Upcoming Milestones

• Advance VSELs into a Phase Ia safety trial for macular degeneration (2013)

• PCT – Secure additional client contracts, establish client partnerships for commercial manufacturing and/or royalties, and expand manufacturing outside the U.S. (2012)

• Closing of divestiture of Suzhou Erye (51% NeoStem owned generic pharmaceutical company) (2012)

• Start Phase I trial in CHF with AMR-001 (2012/2013)

• Complete enrollment of Phase II trial (1H-2013)

• Data readouts for Phase II AMR-001 Trial (2H-2013)

• Athelos - data readout from work under independent physician INDs (1H-2013)

• Secure additional SBIR and/or DoD government grants for VSEL Technology (2012)

Contacts

Collaborations

Dr. Robin L. Smith

Chairman and Chief Executive Officer

212.584.4174

rsmith@neostem.com

Gitanjali Jain Ogawa

Trout Group - Vice President

646.378.2949

gogawa@troutgroup.com

This material contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date hereof, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the development of AMR-001 and other cell therapeutics, the future of the cell therapeutics industry, and the Company’s divestiture of its interest in Suzhou Erye Pharmaceutical Co., Ltd. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors including those described under the heading "Risk Factors" in the Company’s filings with the Securities and Exchange Commission (www.sec.gov). The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

NeoStem, Inc. (NYSE MKT: NBS)

420 Lexington Avenue, Suite 450

New York, NY 10170

212.584.4180

www.neostem.com



NeoStem, Inc.
420 Lexington Avenue
Suite 450
New York, New York 10170
Telephone: 212-584-4180
Fax: 646-514-7787


Website: www.neostem.com

Conceptus, RTI International Metals Among Stocks Gapping Up Wednesdayat Fox Business(Wed, Aug 1)
Costly Mistakes Crush Dendreon But Upside May Lurkat Seeking Alpha(Wed, Aug 1)
Celsion and Neostem Showing Positive Growth as Biotech Industry Soaring in 2012Marketwire(Tue, Jul 31)
Are Stem Cells Becoming The Next Bull Market In The Biotech Space?at Seeking Alpha(Mon, Jul 30)
NeoStem's Promising VSEL Developments Are Good Signs For The Future Of Cell Therapyat Seeking Alpha(Thu, Jul 26)
Heavy Volume May Mean Heavier Profits In Small Biopharmaceutical Stocksat Seeking Alpha(Mon, Jul 23)
A Big Win For Neostemat Seeking Alpha(Thu, Jul 19)
NeoStem Continues To Rally Behind Its Key Developmentsat Seeking Alpha(Tue, Jul 17)
NeoStem's Subsidiary, Progenitor Cell Therapy, and SOTIO Enter Into a Phase 3 Manufacturing Services AgreementGlobeNewswire(Mon, Jul 16)
» More Headlines for NBS







Information compiled from public sources